Navigation Links
Omeros Appoints David A. Mann to its Board of Directors
Date:8/13/2008

SEATTLE, Aug. 13 /PRNewswire/ -- Omeros Corporation has announced the appointment of David A. Mann to the Company's Board of Directors. Mr. Mann also serves as Chairman of the Board's audit committee.

"Dave's years of executive management experience in finance and operations in the biotechnology sector are an invaluable asset to Omeros," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "He is an important addition to our Board, and I expect that he will play an integral role as we prepare for product commercialization."

"Dr. Demopulos and his team have done an excellent job in advancing their PharmacoSurgery platform, and I am pleased to be working with them," commented David Mann. "With a deep pipeline focused on inflammation and CNS, Omeros represents an exciting opportunity."

Mr. Mann brings with him over 20 years of executive management, finance and operations experience in the biotechnology industry. He was executive vice president and chief financial officer at Immunex prior to and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center. Mr. Mann serves on the Board of Directors of Trubion Pharmaceuticals, and is on the advisory board of the Western Washington University College of Business and Economics and the Western Washington University Foundation Board. He is a former Certified Public Accountant, and earned his M.B.A. from the University of Washington and a B.A. from Western Washington University.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at http://www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
4. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
5. SAFC Appoints New Vice President of Quality and Regulatory Affairs
6. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
7. ARCA biopharma Appoints James Carr as Vice President of Marketing
8. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
9. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
10. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
11. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... ... R&D, today announced that Immatics Biotechnologies , a clinical-stage biopharmaceutical company ... to streamline their R&D operations related to the discovery and development of ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... (AI)-powered technology for use in pathology research, today announced the results of ... from patients enrolled in the phase 3 selonsertib studies (STELLAR). Strong correlations ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By ... the Fusion Bx 2.0 will give urologists across Europe the ability to perform ...
(Date:11/2/2019)... NEW YORK (PRWEB) , ... October 31, 2019 ... ... just been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s ... data. This new tool allows researchers to quickly uncover relationships between genes, diseases, ...
Breaking Biology Technology:
(Date:11/27/2019)... , ... November 26, 2019 , ... ... to their Glen Ellyn, IL practice for Invisalign® treatment. Invisalign orthodontics ... , Patients with a misaligned bite, also known as malocclusion, present both functional ...
(Date:11/20/2019)... ... November 20, 2019 , ... BioInformatics Inc., part of ... tools market, today announced the winners of the Life Science Industry Awards for the ... Life Science Industry Awards – Innovation: , Most Innovative New Product – Cell Biology, ...
(Date:11/19/2019)... ... November 19, 2019 , ... Hosted at the Las Vegas Convention ... 2019 is the largest gathering of MJBiz business professionals in the world. With ... benefit every sector, there is no show quite like it. Atlantic Ultraviolet will exhibit ...
Breaking Biology News(10 mins):